Neoeriocitrin - CAS:13241-32-2

您当前的位置：

Neoeriocitrin (Synonyms:新北美圣草苷)

目录号 : KCM11043 CAS No. : 13241-32-2 纯度 : ≥98%

Data Sheet SDS 产品使用指南

Neoeriocitrin is a flavonoid that has been found in C. paradisi and has antioxidative and osteogenic activities. It inhibits the production of 2,2-diphenyl-1-picrylhydrazyl (DPPH; ) radicals by 17.2% and the formation of superoxide radicals by 48.3% in cell-free assays, as well as decreases the rate of LDL oxidation ex vivo in isolated hamster plasma. Neoeriocitrin (2 µg/ml) increases proliferation of MC3T3-E1 osteoblast percursor cells and reverses the antiproliferative effect of the MEK1 inhibitor PD 98059 . It also increases the expression of the osteogenic differentiation markers Runx2, Type 1 collagen, and osteocalcin.

规格	价格	是否有货	数量
10 mM * 1 mL in DMSO		In-stock
1mg		In-stock
5mg		In-stock
10mg		In-stock
25mg		In-stock

加入购物车大包装询价

Other Forms of Rapamycin:

4"-Isovalerylspiramycin I In-stock
Higenamine-d4 hydrochloride In-stock
Adebrelimab In-stock
Tigatuzumab In-stock
Cosdosiran In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

Neoeriocitrin is a Naringin analogue found in Drynaria Rhizome. Neoeriocitrin induces cells proliferation, differentiation, up-regulates type I collagen, osteocalcin, and key osteogenic markers, and increases ALP activity. Neoeriocitrin increases expression of Runx2, COL I, OCN and Beclin1. Neoeriocitrin inhibits phosphorylation of P38 mitogen-activated protein kinase, reduces acetylcholinesterase (AChE) activity, and increases choline acetyltransferase (ChAT) activity. Neoeriocitrin reduces apoptosis and induces autophagy. Neoeriocitrin can be used for the researches of osteoporosis and Alzheimer's disease[1].

体外研究

Neoeriocitrin (2-20 μg/mL; 72 h) can dose dependently regulate MC3T3-E1 cell proliferation [1].

Neoeriocitrin (2-20 μg/mL; 5 days) can dose dependently increase ALP activity in MC3T3-E1 cells [1].

Neoeriocitrin (2 μg/mL; 4-8 days) can upregulate the expression of osteogenic marker genes Runx2, COL I, and OCN in MC3T3-E1 cells [1].

Neoeriocitrin (2 μg/mL; 5 days) can partially reverse the inhibitory effect of PD98059 on ALP activity in MC3T3-E1 cells [1].

Neoeriocitrin (2 μg/mL; 4-8 days) can partially reverse the downregulation of COL I and OCN mRNA expression induced by PD98059 in MC3T3-E1 cells [1].

Neoeriocitrin (2.5-200 μM; 1-14 days) can significantly and continuously promote the proliferation of human dental pulp stem cells [2].

Neoeriocitrin (2.5-10 μM; 7-21 days) has the strongest promoting effect on osteogenic differentiation of human dental pulp stem cells, which can be verified by increased expression levels of osteogenic genes and proteins, enhanced alkaline phosphatase activity, and increased mineralization degree [2].

Neoeriocitrin (100 μM; 1 h) can directly bind to Beclin1 in human dental pulp stem cells, as confirmed by the increased thermal stability of Beclin1 in thermal proteomic analysis [2].

Neoeriocitrin (2.5-10 μM; 48 h) can induce autophagy in human dental pulp stem cells. This conclusion is validated by the following indicators: decreased P62 levels, increased LC3-II/I ratio, enhanced autophagosome formation, and increased number of autophagosomes detected by transmission electron microscopy [2].

The process of inducing autophagy and osteogenic differentiation in human dental pulp stem cells by Neoeriocitrin (5 μM) requires Beclin1 as a key mediator, as knocking down Beclin1 weakens this effect, while overexpression of Beclin1 enhances the effect of Neoeriocitrin [2].

Neoeriocitrin (5 μM; 3-12 h) stabilizes Beclin1 protein in human dental pulp stem cells by inhibiting ubiquitin mediated proteasomal degradation, thereby prolonging the half-life of Beclin1 [2].

Neoeriocitrin (6×10⁴ μM; Pre incubation for 2 hours and co incubation with A β 25-35 for 22 hours can protect PC12 cells damaged by A β 25-35 by reducing cell apoptosis, upregulating ER β expression, inhibiting P38 protein phosphorylation, and improving cholinergic system function.

Cell Proliferation Assay

Cell Line:	MC3T3-E1 preosteoblast cells
Concentration:	2, 4, 8, 10, 20 μg/mL
Incubation Time:	72 hours
Result:	Increased proliferation rate at 2 and 4 μg/mL. Decreased proliferation rate at 8-10 μg/mL.

Real Time qPCR

Cell Line:	MC3T3-E1 preosteoblast cells
Concentration:	2 μg/mL
Incubation Time:	4 days (Runx2 and COL I); 8 days (OCN)
Result:	Increased Runx2, COL I and OCN mRNA expression.

Cell Proliferation Assay

Cell Line:	human dental pulp stem cells (hDPSCs)
Concentration:	5, 10, 25, 50, 100, and 200 μM
Incubation Time:	3, 5, 7, and 14 days
Result:	Produced a sustained, significant enhancement of hDPSCs proliferation from day 5 onwards at 2.5, 5, and 10 μM, compared to control or higher concentrations. Stimulated proliferation in the first 3 days at concentrations below 200 μM.

Cell Differentiation Assay

Cell Line:	human dental pulp stem cells (hDPSCs)
Concentration:	2.5, 5, and 10 μM
Incubation Time:	7 days (ALP staining, gene/protein expression); 21 days (alizarin red staining)
Result:	Most significantly upregulated osteogenesis-related mRNA (Collagen I, ALP, OPN, Runx2) and protein (Collagen I, ALP, OPN, Runx2) expression. Showed the largest positive area percentage in ALP staining at 7 days with 5 μM. Showed the highest mineralization in alizarin red staining at 21 days with 5 μM.

Cell Autophagy Assay

Cell Line:	human dental pulp stem cells (hDPSCs)
Concentration:	2.5, 5, and 10 μM
Incubation Time:	48 h
Result:	Significantly reduced P62 protein levels and increased the LC3-II/I ratio at 2.5 and 5 μM. Showed a diminished, non-significant effect on P62 at 10 μM. Increased the number of yellow (RFP⁺GFP⁺) puncta (autophagosomes) and the number of autophagosomes visible via TEM at 5 μM, compared to control.

体内研究

Neoeriocitrin (cultured human dental pulp stem cells (hDPSCs) with Neoeriocitrin for 5 days, then combined with Bio Oss bone graft material at a seeding density of 1 × 10⁷ cells) significantly promotes new bone formation at critical size skull defects in rats, while upregulating the expression of autophagy markers (Beclin1, LC3) and downregulating the expression of P62 in regenerated bone tissue [2].

分子式

C₂₇H₃₂O₁₅

分子量

596.53

CAS号

13241-32-2

中文名称

新圣草次苷

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

-20°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据

In Vitro:

DMSO : 100 mg/mL (167.64 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.6764 mL	8.3818 mL	16.7636 mL
5 mM	0.3353 mL	1.6764 mL	3.3527 mL
10 mM	0.1676 mL	0.8382 mL	1.6764 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂：10% DMSO → 40% PEG300 → 5% Tween-80 → 45% saline

Solubility: ≥ 2.5 mg/mL (4.19 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.19 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
2.

请依序添加每种溶剂： 10% DMSO → 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (4.19 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.19 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD ⽣理盐⽔⽔溶液中，混合均匀。

纯度： ≥98%

Data Sheet

SDS

产品使用指南

[1]. Li L, et al. Comparison of neoeriocitrin and naringin on proliferation and osteogenic differentiation in MC3T3-E1. Phytomedicine. 2011;18(11):985-989.

[2]. Wu Y, et al. Neoeriocitrin Targeting Beclin1 Deubiquitination and Autophagy in Osteogenic Differentiation of Human Dental Pulp Stem Cells. Adv Sci (Weinh). 2025;12(43):e04378.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量

浓度

体积

分子量*

重置计算

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2

浓度

体积

浓度

体积

重置计算

动物实验计算换算器

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系客服为您提供正确的澄清溶液配方）

% DMSO

% Tween 80

% ddH₂O

% DMSO

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系客服）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

配置后的溶液总体积：

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

Other Forms of Rapamycin:

KKL 顾客使用本产品发表的 0 篇科研文献

The molarity calculator equation

The dilution calculator equation

动物实验计算换算器